Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.50 |
| ▸ | EGFR | P00533 | 7/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.50 |
| ▸ | FLT1 | P17948 | 7/20 | 0.50 |
| ▸ | FLT4 | P35916 | 7/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIF5B | P33176 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | ABL2 | P42684 | 3/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20303991 | 0.88 | EHMT2 (0.49) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL20303751 | 0.85 | SRC (0.47) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL20351014 | 0.84 | EHMT2 (0.48) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL20351092 | 0.82 | EHMT2 (0.48) | KDREGFRFGFR1FLT1FLT4 | |
| Formic Acid SCHEMBL20336803 | 0.80 | EGFR (0.44) | KDREGFRFGFR1FLT1FLT4 | |
| Trifluoroacetic Acid SCHEMBL20336945 | 0.79 | WHR1 (0.48) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL20303857 | 0.79 | SPIN1 (0.59) | EHMT2DNMT1 | |
| SCHEMBL19260791 | 0.78 | EHMT2 (0.77) | EHMT2 | |
| SCHEMBL20304093 | 0.77 | SPIN1 (0.59) | EHMT2DNMT1 | |
| Formic Acid SCHEMBL19260576 | 0.76 | EHMT2 (0.70) | EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063358-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4063358-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-3558971-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10829452-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3558971-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| WO-2018119208-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | KDR 4621/4885EGFR 4854/4885FGFR1 4823/4885 |
| US-10829452-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | KDR 2905/4885EGFR 4205/4885FGFR1 3115/4885 |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | KDR 4621/4885EGFR 4854/4885FGFR1 4823/4885 |
| US-11713299-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | KDR 2896/4885EGFR 4209/4885FGFR1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.